Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - February 2013


Parallel Trade

06 Feb 2013 - 07 Feb 2013 - London, UK



Bookmark and Share


SMi are proud to present their 7th annual Parallel Trade conference. 

Our 2013 agenda will showcase the latest developments in pharmaceutical Parallel Trade, looking at the industry’s rapid expansion and latest arguments from key opinion leaders on this controversial industry. Hear from experts in leading industry sectors; see how big Pharma companies are beginning to combat traders and attempt to prevent counterfeit medicines entering the market. Through case studies see how trading can affect future R&D pipelines in big pharma drug development. Parallel trade has unique, important legal issues attached to it – hear from specialist pharmaceutical lawyers explaining issues with intellectual property and specific aspects of repackaging. 

Reasons why you should attend:

Hear from the industry leaders on both the advantages and disadvantages to patients, drug producers and traders. How does trading affect your business – New market access or potential hazard? 

See how parallel trade is being maintained from both sides of the fence, supply chain protection and specific aspects of repackaging.

Learn how the financial euro crisis has allowed an increase in need for more affordable drugs to supply harder hit countries but also put an increased pressure on pharmaceutical companies who pay for drug development.

Visit our website here: http://www.smi-online.co.uk/2013paralleltrade12.asp

Alternatively Contact Fateja Begum on telephone +44 (0) 20 7827 6184 or email on fbegum@smi-online.co.uk

Quote “Technology Network” and save £100




Further information
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!